--- schema_version: "secwatch.filing_event.v1" accession: "0001193125-24-158772" form_type: "8-K" ticker: null cik: "0001654151" company_name: "Deciphera Pharmaceuticals, Inc." filed_at: "2024-06-11T23:59:59+00:00" generated_at: "2026-06-01T05:04:39.608684+00:00" event_type: "m_and_a" sentiment: "neutral" materiality_score: 0.9 calibrated_materiality_score: 0.9 confidence: "high" source: SEC EDGAR --- # Ono completes $2.4B acquisition of Deciphera; shares converted at $25.60 each ## Summary - 88.3% of shares tendered; all conditions satisfied; merger effective June 11, 2024. - Each share converted to $25.60 cash; total consideration approx. $2.4 billion. - Deciphera becomes wholly owned subsidiary of Ono; board replaced by Toichi Takino and Masayuki Tanigawa. - Nasdaq listing suspended; Form 15 to be filed to terminate SEC reporting obligations. - 2024 Annual Meeting cancelled due to closing of the merger. ## SEC filing metadata - accession: 0001193125-24-158772 - form_type: 8-K - cik: 0001654151 - company_name: Deciphera Pharmaceuticals, Inc. - filed_at: 2024-06-11T23:59:59+00:00 - event_type: m_and_a - sentiment: neutral - materiality_score: 0.9 - calibrated_materiality_score: 0.9 - confidence: high - sec_items: 1.02, 2.01, 3.01, 3.03, 5.01, 5.03, 5.02, 8.01, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/d824393d8k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001193125-24-158772 - JSON: https://secwatch.observer/filing/0001193125-24-158772.json - Plain text: https://secwatch.observer/filing/0001193125-24-158772.txt ## Key facts - Executive change Toichi Takino was appointed as Director at Deciphera Pharmaceuticals, Inc.. - Action: appointed - Role: Director source text: Toichi Takino and Masayuki Tanigawa became members of Deciphera’s board of directors evidence_url: https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm - Executive change Dennis L. Walsh resigned as Director at Deciphera Pharmaceuticals, Inc.. - Action: resigned - Role: Director source text: Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera evidence_url: https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm - Executive change James A. Bristol resigned as Director at Deciphera Pharmaceuticals, Inc.. - Action: resigned - Role: Director source text: Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera evidence_url: https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm - Executive change Ron Squarer resigned as Director at Deciphera Pharmaceuticals, Inc.. - Action: resigned - Role: Director source text: Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera evidence_url: https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm - Executive change Frank S. Friedman resigned as Director at Deciphera Pharmaceuticals, Inc.. - Action: resigned - Role: Director source text: Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera evidence_url: https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm - Executive change Patricia L. Allen resigned as Director at Deciphera Pharmaceuticals, Inc.. - Action: resigned - Role: Director source text: Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera evidence_url: https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm - Executive change Susan L. Kelley resigned as Director at Deciphera Pharmaceuticals, Inc.. - Action: resigned - Role: Director source text: Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera evidence_url: https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm - Executive change Edward J. Benz, Jr. resigned as Director at Deciphera Pharmaceuticals, Inc.. - Action: resigned - Role: Director source text: Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera evidence_url: https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm - Executive change Masayuki Tanigawa was appointed as Director at Deciphera Pharmaceuticals, Inc.. - Action: appointed - Role: Director source text: Toichi Takino and Masayuki Tanigawa became members of Deciphera’s board of directors evidence_url: https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm - Executive change John R. Martin resigned as Director at Deciphera Pharmaceuticals, Inc.. - Action: resigned - Role: Director source text: Ron Squarer, Patricia L. Allen, Edward J. Benz, Jr., Frank S. Friedman, James A. Bristol, Susan L. Kelley, John R. Martin and Dennis L. Walsh resigned as directors of Deciphera evidence_url: https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm - M&A Transactions Deciphera Pharmaceuticals, Inc. underwent a change of control involving Ono Pharmaceutical Co., Ltd. for $25.60 per share in cash (closed 2024-06-11). - Action: change of control - Counterparty: Ono Pharmaceutical Co., Ltd. - Consideration: $25.60 per share in cash - Closing: 2024-06-11 source text: May 13, 2024 to acquire all of the issued and outstanding shares of common stock, par value $0.01 per share, of the Company (“ Company Common Stock ”), at a price per share of $25.60, net to the seller in cash, without interest and subject to any withholding of taxes required by applicable law. The Offer and related withdrawal rights expired at one minute evidence_url: https://www.sec.gov/Archives/edgar/data/1654151/000119312524158772/0001193125-24-158772-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.